In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

“I’m here for breast cancer. Why are you talking to me about my heart?”

Call for Action: Study reveals urgent need to look after hearts of cancer patients

Cardiotoxicity of Drugs
Risk Factors and Prevention

Milan, Italy – 4 May 2019: Many physicians are not telling cancer patients about the cardiotoxicity risks of treatments and may not be fully aware of the dangers themselves. A new study reveals an urgent need to look after the hearts of these patients. The research is presented today at EuroHeartCare 2019, a scientific congress of the European Society of Cardiology (ESC).1

“There was no mention that it could lead to heart disease. Would have been nice to know.”

The growing number of cancer survivors and increasing number of over-65s needing chronic cancer therapy mean that the need for cardio-oncology services is rising. Heart failure caused by cancer therapy can occur up to 20 years after treatment. In 2012 over 32 million people worldwide were living with cancer.2

“Depending on the type of chemotherapy and radiotherapy, between 1% and 25% cancer patients may develop heart failure due to cancer treatment,” said study author Professor Robyn Clark, of Flinders University, Adelaide, Australia. “Risk also depends on cardiovascular risk factors such as smoking and obesity. Better monitoring of the heart and intervention before, during and after treatment can prevent or lessen the impact of this cardiotoxicity.”

The researchers reviewed medical records of 46 randomly selected cancer patients with cardiotoxicity who attended one of three hospitals between 1979 and 2015. Just 11% were referred to a cardiologist before chemotherapy and less than half (48%) were referred to a heart failure clinic after cancer treatment. Almost 40% were overweight or obese, 41% were current or ex-smokers, 24% were regular consumers of alcohol, 48% had hypertension, and 26% had diabetes.

In a subset of patients, practice was compared before (1994–2011) and after (2012–2015) the 2012 European Society for Medical Oncology guidelines were published.3 Referral to a cardiologist before chemotherapy rose from 0 to 23% and conducting a baseline echocardiogram of the heart increased from 57% to 77%.

Eleven patients were interviewed, of whom seven were involved in the medical records analysis. No patient could articulate their heart health needs. More than half said they started eating healthily after their cancer diagnosis yet appeared to lack understanding of a balanced diet.

The ESC published recommendations in 20164 and in 2018 launched the ESC Council of Cardio-Oncology to promote the prevention, early diagnosis, and management of cancer therapy-related cardiovascular diseases. Patients should be told the risks to their heart before starting cancer therapy, given help to quit smoking, eat healthily, exercise, and control their weight, and told to report signs and symptoms of cardiovascular disease.

Cardiotoxicity is detected using electrocardiogram (ECG), cardiac imaging, and biomarkers. The frequency of assessment depends on a number of factors – for example, evaluation for coronary artery disease, ischaemia and vascular disease is recommended in patients with a history of mediastinal radiation starting five years post-treatment and then at least every five years thereafter, even if they have no symptoms.

Angiotensin-converting enzyme (ACE) inhibitors or beta-blockers may be given to prevent or treat heart failure. And cancer therapy can be modified – for example reducing the dose or having a gap between two agents which raise heart failure risk when taken together (e.g. anthracyclines and trastuzumab).

“Monitoring the heart throughout the cancer journey can ensure it is protected,” said Professor Clark. “Cardiotoxicity can occur even in people without cardiovascular risk factors since drugs like anthracyclines and trastuzumab are toxic to the heart, so it is an innocent bystander.”

“For cancer patients who do develop heart failure, there are clinics that will improve their quality of life but our study shows many are not referred,” she added. “Telephone calls to support and monitor those with cancer and heart failure would reduce the burden of hospital appointments, which patients said was a priority.”


Notes to editor

 Authors: ESC Press Office
Tel: +33 (0)4 8987 2499
Mobile: +33 (0)7 8531 2036

Follow us on Twitter @ESCardioNews 

The hashtag for EuroHeartCare 2019 is #euroheartcare.


Funding: This project was funded by a Heart Foundation Vanguard Grant (App ID: 100596- 2014). Professor Robyn A Clark is supported by a Heart Foundation Future Leader Fellowship (App ID:100847).

Disclosures: None.

References and notes

1The abstract ‘Establishing a practice gap to inform the implementation of more effective cardio-oncology clinical services: a retrospective audit examining the clinical management of patients with cardiotoxicity’ will be presented during Moderated poster session – Heart Failure on Saturday 4 May at 10:45 to 11:45 CEST in the Moderated Poster Area.


3Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 (Suppl 7):vii155–vii166. doi:10.1093/annonc/mds293.

4Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768–2801. doi:10.1093/eurheartj/ehw211.

About the Association of Cardiovascular Nursing & Allied Professions

The mission of the Association of Cardiovascular Nursing & Allied Professions (ACNAP) is to support nurses and allied health professionals throughout Europe to deliver the best possible care to patients with cardiovascular disease and their families.

About EuroHeartCare

EuroHeartCare is the annual Congress of the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the European Society of Cardiology (ESC).

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.


Information for journalists attending EuroHeartCare 2019

EuroHeartCare 2019 will be held 2 to 4 May at the Milano Convention Centre (MiCo) in Milan, Italy. Explore the scientific programme.

  • To register on-site please bring a valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event).
  • Press registration is not available to industry or its public relations representatives, event management, marketing or communications representatives.